psoriasis


Over $40,000 raised – NPF Walk for Cure

Thanks to all who participated in this year’s National Psoriasis Foundation walk in Dallas/FW raising over $40,000 towards psoriasis research.  Dr. Alan Menter was chosen as Honorary Medical Chair, celebrating  his contributions of serving the psoriatic disease community in Dallas/Fort Worth.  Meet and read more about this year’s 2017 regional NPF […]

MPF Walk DFW 2017

FDA Approves New Medication for Plaque Psoriasis

FDA Approves New Medication for Plaque Psoriasis   On January 1, 2015, the United States Food & Drug Administration approved Cosentyx (secukinumab) for use in moderate to severe plaque psoriasis. Cosentyx is the first injectable medication approved for psoriasis which targets IL-17A, a molecule responsible for psoriatic inflammation. The safety […]


MDRI – Seeking Participants – Psoriasis Clinical Trials

MDRI adds two new clinical trials for Psoriasis The Menter Dermatology Research Institute is seeking participants for two new psoriasis clinical trials as well as participants for many ongoing studies.  Please contact us if you need more information on any of our clinical research studies.   For further information on all of our clinical trials, […]


Psoriasis Nails

Nail Psoriasis Treatment – National Psoriasis Foundation’s Recommendations

Nail Psoriasis Treatment – Published Guidelines Nail psoriasis is a burden to many psoriasis patients, is difficult to treat, and has no standardized treatment algorithm. The Medical Board of the National Psoriasis Foundation recently published guidelines for the treatment of nail psoriasis. These treatment recommendations spanned four nail psoriasis scenarios […]


MDRI – New Clinical Trials for Psoriasis and Eczema

MDRI adds several new clinical trials for Psoriasis and Eczema We are actively seeking participants. Contact us if you need more information on any of our clinical research studies.   For further information on all clinical trials, visit our Clinical Trials page. Eligibility – Psoriasis Moderate to Severe Plaque Type Psoriasis Ages:  18 […]